TLC to Present at Berenberg Pain SeminarDownload
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced today that the Company’s management team will be presenting its product candidates in pain management –TLC599 for osteoarthritis knee pain and TLC590 for postsurgical pain – at the Berenberg Pain Seminar on Wednesday, November 13, 2019 at the Berenberg offices in New York.
TLC599 is a non-opioid, proprietary BioSeizer® sustained release formulation of dexamethasone intended to manage osteoarthritis pain for up to six months; TLC590 is a non-opioid, BioSeizer® formulation of ropivacaine with the potential to manage postsurgical pain for four to seven days with a single dose. TLC599 and TLC590, which are currently in their Phase III and Phase II clinical trials, respectively, have the potential to deter or avoid the use of addictive opioids.
The seminar will include panel discussions and presentations featuring influential figures and experts in pain management. George Yeh, President of TLC, will be making the company introduction alongside peers in the pain management landscape, including Arena Pharmaceuticals, Flexion Therapeutics, Pacira BioSciences and Recro Pharma.